Brokerages expect OpGen, Inc. (NASDAQ:OPGN) to post $860,000.00 in sales for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for OpGen’s earnings, with estimates ranging from $760,000.00 to $950,000.00. OpGen posted sales of $730,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 17.8%. The firm is expected to announce its next quarterly earnings results on Monday, October 23rd.

On average, analysts expect that OpGen will report full-year sales of $860,000.00 for the current year, with estimates ranging from $2.98 million to $3.71 million. For the next fiscal year, analysts forecast that the firm will report sales of $6.70 million per share, with estimates ranging from $3.40 million to $10.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that follow OpGen.

A number of equities research analysts recently issued reports on the company. Dawson James reissued a “buy” rating on shares of OpGen in a research note on Monday, June 19th. Zacks Investment Research raised OpGen from a “sell” rating to a “hold” rating in a research note on Wednesday, June 28th. Finally, HC Wainwright set a $1.00 price target on OpGen and gave the stock a “buy” rating in a research note on Wednesday, August 9th.

In other OpGen news, CFO Timothy C. Dec purchased 65,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 18th. The stock was purchased at an average cost of $0.40 per share, with a total value of $26,000.00. Following the purchase, the chief financial officer now owns 118,966 shares of the company’s stock, valued at $47,586.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Jven Capital, Llc purchased 1,875,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 18th. The shares were acquired at an average cost of $0.40 per share, with a total value of $750,000.00. The disclosure for this purchase can be found here. 53.27% of the stock is currently owned by company insiders.

A hedge fund recently raised its stake in OpGen stock. Vanguard Group Inc. raised its position in shares of OpGen, Inc. (NASDAQ:OPGN) by 1.6% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 342,860 shares of the medical research company’s stock after purchasing an additional 5,500 shares during the period. Vanguard Group Inc. owned about 1.25% of OpGen worth $219,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 8.13% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This piece was posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/09/17/860000-00-in-sales-expected-for-opgen-inc-opgn-this-quarter.html.

Shares of OpGen (OPGN) opened at 0.2829 on Friday. The stock’s market capitalization is $14.59 million. The company’s 50 day moving average price is $0.30 and its 200 day moving average price is $0.63. OpGen has a 52-week low of $0.27 and a 52-week high of $3.10.

About OpGen

OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.

Get a free copy of the Zacks research report on OpGen (OPGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for OpGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.